Vts-K
Peripheral Nervous System Agents
Theresa Jacob, PhD, MPHPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Peripheral Nervous System Agents cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Theresa Jacob, PhD, MPH | Phase 3 | B |
MIDAZOLAM Theresa Jacob, PhD, MPH | Phase 3 | B |
Cynk-001 Celularity Incorporated | Phase 1 | D |
Same molecule, other indications
Vts-K is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →